---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-133759"
form_type: "8-K"
ticker: "TEVA"
cik: "0000818686"
company_name: "TEVA PHARMACEUTICAL INDUSTRIES LTD"
filed_at: "2024-05-08T23:59:59+00:00"
generated_at: "2026-06-02T14:48:37.208017+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Teva Q1 revenue $3.8B (+4% YoY), non-GAAP EPS $0.48, reaffirms FY24 guidance

## Summary
- Revenue $3.819B (+4% YoY, +5% local currency); generics up 9% globally.
- AUSTEDO U.S. sales up 67% YoY; AJOVY $113M (+18% YoY).
- Non-GAAP diluted EPS $0.48 (vs $0.40); GAAP loss per share $0.12 (vs $0.20 loss).
- FY2024 guidance reaffirmed: revenue $15.7-16.3B, non-GAAP EPS $2.20-2.50, free cash flow $1.7-2.0B.
- Positive Phase 3 efficacy results for olanzapine LAI (TEV-749) for schizophrenia; no PDSS observed.

## SEC filing metadata
- accession: 0001193125-24-133759
- form_type: 8-K
- ticker: TEVA
- cik: 0000818686
- company_name: TEVA PHARMACEUTICAL INDUSTRIES LTD
- filed_at: 2024-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/818686/000119312524133759/0001193125-24-133759-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/818686/000119312524133759/d801848d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-133759
- JSON: https://secwatch.observer/filing/0001193125-24-133759.json
- Plain text: https://secwatch.observer/filing/0001193125-24-133759.txt

## Key facts
- Earnings Releases
  TEVA PHARMACEUTICAL INDUSTRIES LTD reported the quarter ended March 31, 2024 results: revenue $3,819 million, EPS GAAP loss per share of $0.12. Guidance reaffirmed.
  - Period: the quarter ended March 31, 2024
  - Revenue: $3,819 million
  - EPS: GAAP loss per share of $0.12
  - Guidance: reaffirmed
  - Result: reported results
  source text: TEVA REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS AND REAFFIRMS 2024 FINANCIAL OUTLOOK • Generics business and AUSTEDO ® growth lead Q1 2024 performance. • Q1 2024 revenues of $3.8 billion reflect an increase of 5% in local currency terms, compared to Q1 2023. • Generics business growth across all regions – increased by 9% in local currency terms globally, compared
  evidence_url: https://www.sec.gov/Archives/edgar/data/818686/000119312524133759/0001193125-24-133759-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.